The use of hematopoietic growth factors to support cytotoxic chemotherapy for patients with breast cancer.
The rationale for the uses of hematopoietic growth factors in the treatment of breast cancer is reviewed. The historical background of development of these novel therapeutic agents is also summarized as it pertains to patients undergoing myelosuppressive treatments. Important areas of controversy in the clinical uses of hematopoietic growth factors are identified, and future research directions in this field are discussed.
Demetri
G D
GD
Department of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000517:prevention & control*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D006801:Humans
D016298:Hematopoietic Cell Growth Factors